These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20359536)

  • 1. Drug discovery in the p53 field.
    Lain S
    Semin Cancer Biol; 2010 Feb; 20(1):1-2. PubMed ID: 20359536
    [No Abstract]   [Full Text] [Related]  

  • 2. The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen.
    McCarthy AR; Hollick JJ; Westwood NJ
    Semin Cancer Biol; 2010 Feb; 20(1):40-5. PubMed ID: 20206696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent patents related to p53.
    Nat Rev Drug Discov; 2014 Mar; 13(3):169. PubMed ID: 24577392
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic targeting of p53 by small molecules.
    Selivanova G
    Semin Cancer Biol; 2010 Feb; 20(1):46-56. PubMed ID: 20206268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulating the p53 pathway.
    Dey A; Lane DP; Verma CS
    Semin Cancer Biol; 2010 Feb; 20(1):3-9. PubMed ID: 20193765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapy.
    Bremer E; Helfrich W
    Discov Med; 2006 Jun; 6(33):113-7. PubMed ID: 17234145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer. DNA damage, deamidation, and death.
    Li C; Thompson CB
    Science; 2002 Nov; 298(5597):1346-7. PubMed ID: 12434041
    [No Abstract]   [Full Text] [Related]  

  • 8. Current strategies to target p53 in cancer.
    Chen F; Wang W; El-Deiry WS
    Biochem Pharmacol; 2010 Sep; 80(5):724-30. PubMed ID: 20450892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents.
    Keyomarsi K; Pardee AB
    Prog Cell Cycle Res; 2003; 5():527-32. PubMed ID: 14593747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [P53 protein: a new tool for the clinician?].
    Laurent-Puig P
    Gastroenterol Clin Biol; 1995 May; 19(5):463-4. PubMed ID: 7589996
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity.
    Itaya M; Yoshimoto J; Kojima K; Kawasaki S
    Methods Mol Med; 2005; 110():213-27. PubMed ID: 15901938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development for and clinical trials of molecular targeting drugs].
    Takashima A; Fukuda H; Shibata T
    Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257
    [No Abstract]   [Full Text] [Related]  

  • 13. [Front-line drug discovery system for cancer].
    Mizukami T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics and metabolomics in cancer drug development.
    D'Alessandro A; Zolla L
    Expert Rev Proteomics; 2013 Oct; 10(5):473-88. PubMed ID: 24117204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
    Poon E; Harris AL; Ashcroft M
    Expert Rev Mol Med; 2009 Aug; 11():e26. PubMed ID: 19709449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway.
    Luu Y; Bush J; Cheung KJ; Li G
    Exp Cell Res; 2002 Jun; 276(2):214-22. PubMed ID: 12027451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis.
    Jiang M; Wei Q; Wang J; Du Q; Yu J; Zhang L; Dong Z
    Oncogene; 2006 Jul; 25(29):4056-66. PubMed ID: 16491117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE
    Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
    [No Abstract]   [Full Text] [Related]  

  • 20. The p53 pathway as a target in cancer therapeutics: obstacles and promise.
    Mandinova A; Lee SW
    Sci Transl Med; 2011 Jan; 3(64):64rv1. PubMed ID: 21209413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.